Background and Objectives: Community-acquired pneumonia (CAP) remains a major health burden worldwide, with high morbidity and mortality, particularly among older adults and those with comorbidities. This study aimed to evaluate the etiological factors of CAP and to investigate systemic inflammatory markers (IL-6, IL-8, IFN-γ, and G-CSF) in blood samples collected from CAP patients to identify which markers could be targets for potential etiological, clinical, and therapeutic interventions. Materials and Methods: A prospective study was conducted in 41 patients with confirmed CAP hospitalised during the winter season of 2024–2025. Clinical, demographic, and laboratory data were collected at admission and seven days later. Serum IL-6, IL-8, IFN-γ, and G-CSF concentrations were measured using a multiplex assay. Results: Aetiology was identified in 87.8% of cases, with typical bacterial pathogens being more prevalent among older, smoking patients, while atypical pathogens were more common among younger, non-smoking patients. Hospitalisation and increased inflammatory markers were associated with older age. After seven days of treatment, significant decreases in IL-6, IFN-γ, and G-CSF concentrations were observed. IFN-γ levels were significantly higher in patients with atypical aetiology. Higher concentrations of IL-8 and G-CSF were associated with hospitalisation. IL-6 levels were positively correlated with age, C-reactive protein (CRP), and pneumonia severity index (PSI) scores. Conclusions: Systemic inflammatory markers, especially IL-6, IL-8, IFN-γ, and G-CSF, may be valuable tools in managing generalised pneumonia. They can help to differentiate etiologically, assess disease severity, and make treatment decisions.

The Comparison of the Copenhagen Burnout Inventory and the Maslach Burnout Inventory in Evaluation of Professional Stress and Burnout among Medical

Psoriazė – lėtinė uždegiminė (autoimuninė) odos liga, varginanti daug pacientų pasaulyje, Europoje ir Lietu­voje. Lietuvoje psoriaze serga daugiau nei 25000 žmonių ir kasmet sergamumas didėja [1]. Psoriazės gydymas ir patogenezė yra itin svarbus dermatologijos tyrimų objek­tas. Per keletą dešimtmečių psoriazės gydymas keitėsi, tobulėjo. Pirmiausia skirti vietinio poveikio preparatai buvo papildyti fototerapija, skiriami fitopreparatai. Vė­liau atsirado galimybė taikyti biologinę terapiją psoria­zės gydymui, kuri laikoma itin dideliu psoriazės gydymo atradimu. Nuo 1990 m., kai buvo atrastas etanerceptas, plačiai psoriazės gydymui taikytas TNF-α inhibitorius, biologinė terapija gerokai patobulėjo, taikoma specifinių interleukinų (taikinių) terapija toliau gerina ligos eigą ir prognozes. Atrasti IL-17 ir IL-23 inhibitoriai – monoklo­niniai antikūnai tęsia šį kelią. Dabar bandoma išsiaiškinti, kaip šių vaistų pritaikymas gali būti plėtojamas psoriazės gydymui dar plačiau.